Wellness
Using ‘biological age’ to predict early colorectal cancer risk

New research suggests that a person’s biological age, which can be higher than his or her chronological age – a concept called accelerated ageing – may predict who’s at risk for developing colon polyps, a known risk factor for colorectal cancer.
The findings link accelerated ageing to increased early colorectal cancer risk and indicate that those ageing faster than their actual age – accelerated agers – may benefit from early colon-cancer screening.
Early detection has been shown to improve both treatment options and outcomes for this disease.
Unlike chronological age, which simply counts years lived, biological age is based on physiological markers that reflect the impact of genetics, lifestyle choices and environmental factors. It’s determined through sophisticated DNA analysis.
“Biological age is an interesting concept, and it leads to the idea of accelerated ageing, when your biological age exceeds your chronological age,” explained Shria Kumar, a colorectal cancer researcher at Sylvester and the study’s senior and corresponding author.
For example, she added, if someone is 50, but his or her biological age is 55, that’s five years of accelerated ageing that might be reflected in overall body functioning.
“It sounds pretty theoretical, but actually accelerated ageing has been shown to be predictive of time to death and even of multiple cancers,” Kumar continued, noting that this line of research adds to a growing area of study within epigenetics, which examines the mechanisms behind deteriorating cell functions.”
Rising rates in younger people
Colorectal cancer rates in people under 50, called early-onset colorectal cancer, have been rising. Since 2011, these rates have been increasing by 2 per cent a year in people younger than 50, according to the American Cancer Society.
Accordingly, researchers have been striving to determine the best age to begin screening for colorectal cancer. The U.S. Preventive Services Task Force has lowered its recommended starting age from 50 to 45.
However, this change might not be sufficient to fully address the problem, Kumar noted, because half of early-onset colorectal cancers occur in people under 45, according to the latest statistics from the National Cancer Institute.
Screening methods
There are several ways to screen for colon cancer now, including more convenient stool-sample tests collected at home. But colonoscopy, a more invasive outpatient procedure that requires sedation in a medical facility, remains the gold standard.
During a colonoscopy, the doctor can identify and remove polyps, which are soft-tissue growths that can lead to cancer. Polyps are common, affecting about 20 per cent to 30 per cent of adults, and removing them during colonoscopy can prevent colon cancer.
“What’s really, I think, exciting about the opportunity in colorectal cancer is that we have a clear prevention tactic,” Kumar said. “Colonoscopy is not only early detection, but also cancer prevention.”
Analysing biological age
Some factors that raise a person’s risk of early-onset colorectal cancer also elevate biological age. These include obesity, smoking, alcohol consumption and other lifestyle habits.
For this study, Kumar and Sylvester colleagues Chloe Brown and Maria Yow investigated biological age as a risk factor for colorectal cancer by studying people under 50 who were having colonoscopies.
The team assessed patients’ biological age through extensive DNA analysis of blood samples and compared it with their colonoscopy results.
They discovered that each year of accelerated ageing correlated with a 16 per cent increased risk of developing polyps. Interestingly, the study did not link other factors, such as body-mass index and smoking history, to polyp risk. But it did find that gender was the strongest risk factor for polyps.
“While I think the biological age finding is interesting and, maybe, exciting, the strongest risk factor for having a pre-cancerous polyp remains male sex,” Kumar explained.
“While we continue to look at biological age and other risks, we also need to evaluate why sex is such a differential risk factor.”
Key takeaways
The authors believe risk-based screening for colorectal cancer focused on people with accelerated ageing could yield beneficial results.
“If we can develop a practical model to really identify and target higher risk people and put them through colonoscopy, we can prevent their cancers,” Kumar explained.
She noted that her team will need to conduct more research with larger sample sizes to obtain a clearer picture.
“Ageing is multifaceted, and we need larger studies to establish whether most people’s biological age is the same as their chronological age,” she said.
“It is pretty striking that multiple studies, including ours, have found that biological age provides distinct health information and that could help us prevent cancer.”
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.












